Docoh
Loading...

BZYR Burzynski Research Institute

Burzynski Research Institute, Inc. (the “Company”) was incorporated under the laws of the State of Delaware in 1984 in order to engage in the research, production, marketing, promotion and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids which are known under the trade name “Antineoplastons.” The Company believes Antineoplastons are useful in the treatment of human cancer and is currently reviewing data of its Phase II clinical trials of Antineoplastons relating to the treatment of various cancers. Antineoplastons have not been approved for sale or use by the Food and Drug Administration of the United States Department of Health and Human Services (“FDA”) or anywhere in the world. In the event Antineoplastons receive such approval and are registered in the United States, Canada, or Mexico, of which there can be no assurance, the Company will commence commercial operations, which shall include the production, marketing, promotion and sale of Antineoplastons in the United States, Canada, or Mexico. In 2004, the FDA approved the designation of Antineoplastons as an “orphan drug” under the Orphan Drug Act of 1983. See “Orphan Drug Designation” below for a detailed description of this designation and its meaning. The Company currently provides Antineoplastons solely for use by Stanislaw R. Burzynski, M.D., Ph.D. (“Dr. Burzynski”) in clinical research.

Company profile

Ticker
BZYR
Exchange
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
760136810

Calendar

15 Jul 21
31 Jul 21
28 Mar 22
Quarter (USD)
May 21 Feb 21 Nov 20 Aug 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Feb 21 Feb 20 Feb 19 Feb 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 594 594 594 594 594 594
Cash burn (monthly) (positive/no burn) (positive/no burn) 105.43K 96.67K 28.15K 32.94K
Cash used (since last report) n/a n/a 212.71K 195.05K 56.79K 66.47K
Cash remaining n/a n/a -212.12K -194.45K -56.19K -65.87K
Runway (months of cash) n/a n/a -2.0 -2.0 -2.0 -2.0

Beta Read what these cash burn values mean

Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
7th grade Avg
New words: Codification, xNo
Removed: increase

Registration and prospectus

No filings

Proxies

No filings